CCN1 Enhances Tumor Immunosuppression through Collagen‐Mediated Chemokine Secretion in Pancreatic Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202500589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Hongjie Fan und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, Chin…. Hauptthemen laut MEDLINE: Cysteine-Rich Protein 61, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Collagen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense, immunosuppressive tumor microenvironment (TME) that limits therapeutic efficacy. This study investigates the role of cellular communication network factor 1 (CCN1, also known as Cyr61), an extracellular matrix‐associated protein, in modulating the TME of PDAC. It is demonstrated that Ccn1 promotes PDAC progression by upregulating collagen and chemokine expression, thereby facilitating immune cell exclusion and enhancing tumor growth. Using a Ccn1‐deficient PDAC model, decreased collagen and chemokine levels are observed, resulting in increased infiltration of cytotoxic immune cells and reduced myeloid‐derived suppressor cells (MDSCs). Furthermore, Ccn1‐deficient tumors exhibit heightened sensitivity to gemcitabine and show enhanced responsiveness to anti‐programmed cell death 1 (anti‐PD1) therapy. Mechanistically, Ccn1 regulates chemokine production through collagen expression, with chemokine levels remaining suppressed even upon interferon‐gamma treatment in collagen‐deficient cells. These findings highlight Ccn1 as a potential therapeutic target that reprograms the TME to enhance the efficacy of both chemotherapy and immunotherapy in PDAC, providing a novel approach for overcoming immune resistance in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China.
- Ganjiang Chinese Medicine Innovation Center, Nanchang, 330000, China.
- Department of Pathology, Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, China.
- Department of Pathology, Xinhua Hospital Affiliated to Medicine School of Shanghai Jiaotong University, Shanghai, 200082, China.
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100006, China.
- Department of Mathematics, University of Maryland, College Park, Maryland, MD 20742, USA.
ORCID-Profile: Yang Chen
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province
- Natural Science Foundation of Hubei Province
Zitieren
APA
Fan, H., Zhao, H., Gao, L., Dong, Y., Zhang, P., Yu, P., Ji, Y., Chen, Z. S., Liang, X., & Chen, Y. (2025). CCN1 Enhances Tumor Immunosuppression through Collagen‐Mediated Chemokine Secretion in Pancreatic Cancer. Advanced Science. https://doi.org/10.1002/advs.202500589
Vancouver
Fan H, Zhao H, Gao L, Dong Y, Zhang P, Yu P, et al. CCN1 Enhances Tumor Immunosuppression through Collagen‐Mediated Chemokine Secretion in Pancreatic Cancer. Advanced Science. 2025. doi:10.1002/advs.202500589
BibTeX
@article{Fan2025,
author = {Fan, Hongjie and Zhao, Huzi and Gao, Lili and Dong, Yucheng and Zhang, Pei and Yu, Pengfei and Ji, Yunfei and Chen, Zhe-Sheng and Liang, Xinmiao and Chen, Yang},
title = {CCN1 Enhances Tumor Immunosuppression through Collagen‐Mediated Chemokine Secretion in Pancreatic Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202500589}
}
EUVIMED